

Lecture consigliate

- Ai Y, Meng Y, Yan B, *et al.* The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death. *Mol Cell* 2024;84:170–9.
- Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation. *Nat Rev Immunol* 2020;20:143–57.
- Chen X, Kang R, Kroemer G, *et al.* Broadening horizons: the role of ferroptosis in cancer. *Nat Rev Clin Oncol* 2021;18:280–96.
- Czabotar PE, Garcia-Saez AJ. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. *Nat Rev Mol Cell Biol* 2023;24:732–48.
- Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. *Cell Death Differ* 2015;22:1071–80.
- Dho SH, Cho M, Woo W, *et al.* Caspases as master regulators of programmed cell death: apoptosis, pyroptosis and beyond. *Exp Mol Med* 2025;57:1121–32.
- Diepstraten ST, Anderson MA, Czabotar PE, *et al.* The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. *Nat Rev Cancer* 2022;22:45–64.
- Galluzzi L, Vacchelli E, Bravo-San Pedro JM, *et al.* Classification of current anticancer immunotherapies. *Oncotarget* 2014;5:12472–508.
- Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov* 2022;12:31–46.
- Kasthuber ER, Lowe SW. Putting p53 in Context. *Cell* 2017;170:1062–78.
- Kayagaki N, Webster JD, Newton K. Control of Cell Death in Health and Disease. *Annu Rev Pathol* 2024;19:157–80.
- Orning P, Lien E. Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. *J Leukoc Biol* 2021;109:121–41.
- Sharma P, Allison JP. The future of immune checkpoint therapy. *Science* 2015;348:56–61.
- Sharma P, Goswami S, Raychaudhuri D, *et al.* Immune checkpoint therapy-current perspectives and future directions. *Cell* 2023;186:1652–69.
- Vogelstein B, Papadopoulos N, Velculescu VE, *et al.* Cancer genome landscapes. *Science* 2013;339:1546–58.
- Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. *Cell* 2009;137:413–31.